Renaissance Technologies (RenTech)'s MLYS Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC (Rentech)) currently holds 322,100 shares of Mineralys Therapeutics, Inc. (MLYS) worth $11.69 M, representing 0.02% of the portfolio. First purchased in 2023-Q3, this medium-term investment has been held for 10 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in MLYS, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2025, adding 274,700 shares. Largest reduction occurred in Q3 2025, reducing 129,526 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Mineralys Therapeutics (MLYS) Holding Value Over Time
Track share changes against reported price movement
Quarterly Mineralys Therapeutics (MLYS) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +274,700 | Add 579.54% | 322,100 | $36.29 |
| Q3 2025 | -129,526 | Reduce 73.21% | 47,400 | $37.92 |
| Q2 2025 | -374 | Reduce 0.21% | 176,926 | $13.53 |
| Q1 2025 | +57,800 | Add 48.37% | 177,300 | $15.88 |
| Q4 2024 | +15,700 | Add 15.13% | 119,500 | $12.31 |
| Q3 2024 | +42,000 | Add 67.96% | 103,800 | $12.11 |
| Q2 2024 | +30,100 | Add 94.95% | 61,800 | $11.70 |
| Q1 2024 | +6,200 | Add 24.31% | 31,700 | $12.90 |
| Q4 2023 | -70,190 | Reduce 73.35% | 25,500 | $8.59 |
| Q3 2023 | +95,690 | New Buy | 95,690 | $9.51 |
Renaissance Technologies (RenTech)'s Mineralys Therapeutics Investment FAQs
Renaissance Technologies (RenTech) first purchased Mineralys Therapeutics, Inc. (MLYS) in Q3 2023, acquiring 95,690 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Mineralys Therapeutics, Inc. (MLYS) for 10 quarters since Q3 2023.
Renaissance Technologies (RenTech)'s largest addition to Mineralys Therapeutics, Inc. (MLYS) was in Q4 2025, adding 322,100 shares worth $11.69 M.
According to the latest 13F filing for Q4 2025, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC (Rentech), owns 322,100 shares of Mineralys Therapeutics, Inc. (MLYS), valued at approximately $11.69 M.
As of the Q4 2025 filing, Mineralys Therapeutics, Inc. (MLYS) represents approximately 0.02% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Mineralys Therapeutics, Inc. (MLYS) was 322,100 shares, as reported at the end of Q4 2025.